Accès libre

Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer

Tanja Ovcaricek
Tanja Ovcaricek
, 
Iztok Takac
Iztok Takac
 et 
Erika Matos
Erika Matos
   | 24 sept. 2019
Radiology and Oncology's Cover Image
À propos de cet article
Article précédent
Article suivant
Citez
Article Category: Review
Publié en ligne: 24 sept. 2019
Pages: 285 - 292
Reçu: 03 janv. 2019
Accepté: 20 juil. 2019
DOI: https://doi.org/10.2478/raon-2019-0038
© 2019 Tanja Ovcaricek, Iztok Takac, Erika Matos, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Estimated survival rates according to risk groups and treatment assigned in the intention-to-treat population

5-year DFS (%) 5-year OS (%)
c-low/g-low 92.8 98.4
c-chemotherapy high/g-low: vs no chemotherapy 92.9 vs. 90.1 98.4 vs. 97.0
c-chemotherapy low/g-high: vs no chemotherapy 92.1 vs. 90.1 97.1 vs. 97.8
c-high/g-high 85.3 94.7

Definition of high clinical risk tumors in MINDACT trial according to lymph node status

Lymph node negative (N = 2114, 64 %) Lymph node positive (N = 1214, 36%)
G1, tumor size > 3 cm G1, tumor size >2 cm
G2, tumor size > 2 cm G2, any size
G3, tumor size > 1 cm G3, any size

Recommendations for the use of multigene signatures in ER-positive, HER-negative breast cancer patients by different expert panels

TEST ASCO NCCN ESMO* St Gallen Group* EGTM
Oncotype DX Ln - , strong Ln Ln -, +, 1 2A IB Yes Ln +/-
MammaPrint Ln Ln -, +, strong moderate Ln -/+, 1 IB Yes Ln +/-
PAM50 Ln -, moderate Ln -/+, 2A IB Yes Ln +/-
EndoPredict Ln -, moderate Ln -/+, 2A IB Yes Ln +/-
BCI Ln -, moderate Ln NR, 2A no Yes Ln -

Estimated survival rates according to recurrence score (RS) and treatment assigned in the intention to treat population (TAILORx trial)

9-year DFS (%) 9-year OS (%)
Low risk; RS ≤ 10, N = 1619 (16.7%) endocrine therapy 84 93.7
Intermediate risk; RS 11–25, N = 3399 (34.9%) endocrine therapy 83.3 93.9
Intermediate risk; RS 11–25, N = 3312 (34%) chemotherapy and endocrine therapy 84.3 93.8
High risk; RS ≥ 26, N = 1389 (14.4%) chemotherapy and endocrine therapy 75.7 89.3

Recurrence score (RS) distribution among studies that validated Oncotype DX in node positive breast cancer (N = 9055)

Study RS low (%) RS intermediate (%) RS high (%)
SWOG S8814 40 28 32
TransATAC 52 31 17
SEER 57 36 7
Clait 53 36 10
PlanB 19 63 19

Distribution of risk groups according to clinical and genomic prediction and treatment assigned in MINDACT trial (N = 6693)

Risk groups Percentage N (%) Treatment regimen
Low genomic clinical and low 2745 (41.0) no chemotherapy
Low clinical and high genomic 592 (8.8) randomization: chemotherapy vs no
High clinical and low genomic 1550 (23.2) randomization: chemotherapy vs no
High genomic clinical and high 1806 (27.0 ) chemotherapy
eISSN:
1581-3207
Langue:
Anglais
Périodicité:
4 fois par an
Sujets de la revue:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
RSS Feed de la revue